Jinsong Lu

Disitamab vedotin triggers ferroptosis to activate CD8+ T-cell antitumor immunity in HER2-expressing breast cancer

Abstract Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is highly aggressive and is associated with poor prognosis after metastasis or recurrence. The development of anti-HER2 antibody–drug conjugates (ADCs) has markedly improved outcomes. Disitamab vedoti...